Table 3.
Comparison of clinical characteristics and metabolic parameters derived from baseline PET in rhabdomyosarcoma patients regarding to the therapy response (N = 13).
| Patients | Therapy response | Z/x2 value | p | |
|---|---|---|---|---|
| CMR (n = 6) | Non-CMR (n = 7) | |||
| Age-median (range) | 4 (1–11 y) | 8 (2.0 mo−13 y) | −1.076 | 0.282 |
| Gender-n (%) | 0.737 | 0.592 | ||
| F | 2 (33.3%) | 4 (57.1%) | ||
| M | 4 (66.7%) | 3 (42.9%) | ||
| Size-n (%) | 0.660 | 0.559 | ||
| <5.0 cm | 2 (33.3%) | 1 (14.3%) | ||
| ≥5.0 cm | 4 (66.7%) | 6 (85.7%) | ||
| SUVmax-median (range) | 5.2 (3.9–7.2) | 9.0 (6.4–15.0) | −2.217 | 0.027 |
| SUVmean-median (range) | 3.6 (2.4–4.6) | 4.3 (3.4–7.3) | −1.791 | 0.073 |
| SUVpeak-median (range) | 3.9 (3.4–5.9) | 6.4 (5.5–9.1) | −2.650 | 0.008 |
| MTV-median (range, cm3) | 43.5 (13.7–196.6) | 402.9 (25.0–824.8) | −2.286 | 0.022 |
| TLG-median (range) | 141.1 (42.6–780.2) | 2362.8 (114.1–4023.3) | −2.429 | 0.015 |
| T –n (%) | 4.550 | 0.070 | ||
| T1 | 3 (50.0%) | 0 (0%) | ||
| T2 | 3 (50.0%) | 7 (100%) | ||
| Lymph node metastases-n (%) | 3.745 | 0.103 | ||
| Yes | 2 (33.3%) | 6 (85.7%) | ||
| No | 4 (66.7%) | 1 (14.3%) | ||
| Distant metastases-n (%) | 3.745 | 0.103 | ||
| Yes | 2 (33.3%) | 6 (85.7%) | ||
| No | 4 (66.7%) | 1 (14.3%) | ||
| Therapy | 0.014 | 0.906 | ||
| Chemotherapy only | 1 (16.7%) | 1 (14.3%) | ||
| Surgery/RT+ chemotherapy | 5 (83.3%) | 6 (85.7%) | ||
T1, confined to anatomic site of origin; T2, extension and or/fixative to surrounding tissue.
F, female; M, male; T, tumor; T1, confined to anatomic site of origin; T2, extension and or/fixative to surrounding tissue; SUVmax, maximum standardized uptake; SUVmean, mean standardized uptake value; SUVpeak, standardized uptake peak value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; RT, radiation; CMR, complete metabolic response.